According to Verastem Oncology 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
Year | P/S ratio | Change |
---|---|---|
2023 | N/A | -100% |
2022 | 32.6 | -82.09% |
2021 | 182 | 4352.97% |
2020 | 4.09 | -33.58% |
2019 | 6.15 | -33.73% |
2018 | 9.28 | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.68 | N/A | ๐บ๐ธ USA |
LabCorp LH | 1.31 | N/A | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.34 | N/A | ๐ฌ๐ง UK |
Curis CRIS | 9.71 | N/A | ๐บ๐ธ USA |